Effects of rapamycin on active heymann nephritis

被引:20
作者
Naumovic, Radomir
Jovovic, Djurdjica
Basta-Jovanovic, Gordana
Miloradovic, Zoran
Mihailovic-Stanojevic, Nevena
Aleksic, Tamara
Jovanovic, Dijana
机构
[1] Clin Ctr Serbia, Inst Urol & Nephrol, Clin Nephrol, Belgrade 11000, Serbia
[2] Fac Med, Med Res Inst, Belgrade, Serbia
[3] Fac Med, Inst Pathol, Belgrade, Serbia
关键词
heymann nephritis; rapamycin; proteinuria; CD8+cells;
D O I
10.1159/000103918
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: The effects of rapamycin ( RAPA) were examined in active Heymann nephritis (HN), an experimental model of human membranous nephropathy (MN). Current opinion on the therapy of MN is controversial, and medications used for its treatment have not yielded the expected results. Methods: In a two-part study, we examined the effects of RAPA (1.5 mg/kg/day) during the induction phase of HN and on the evolving disease. In both parts, control groups of immunized rats not treated with RAPA and control groups of unimmunized rats were observed and sacrificed concurrently with the treated groups. Results: During the induction phase no significant changes in proteinuria were observed in the group treated with RAPA, in comparison to those in the untreated group (p < 0.001). During the evolving disease RAPA significantly lowered proteinuria ( p < 0.001). The characteristic pathohistologic changes and IgG depositions along the glomerular basement membrane were considerably diminished, and infiltration of CD8+ cells completely prevented. Conclusion: RAPA demonstrated beneficial effects on disease progression, given either in the induction phase or during evolving HN. It would be desirable to investigate the effect of RAPA on patients with MN. Copyright (c) 2007 S. Karger AG, Basel.
引用
收藏
页码:379 / 389
页数:11
相关论文
共 31 条
[1]  
Blazar BR, 1998, J IMMUNOL, V160, P5355
[2]   Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy [J].
Bonegio, RGB ;
Fuhro, R ;
Wang, ZY ;
Valeri, CR ;
Andry, C ;
Salant, DJ ;
Lieberthal, W .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (07) :2063-2072
[3]   Sirolimus (rapamycin, Rapamune®) and combination therapy with cyclosporin A in the rat developing adjuvant arthritis model:: Correlation with blood levels and the effects of different oral formulations [J].
Carlson, RP ;
Hartman, DA ;
Ochalski, SJ ;
Zimmerman, JL ;
Glaser, KB .
INFLAMMATION RESEARCH, 1998, 47 (08) :339-344
[4]   EFFECT OF CICLOSPORIN ON ACTIVE HEYMANN NEPHRITIS [J].
CATTRAN, DC .
NEPHRON, 1988, 48 (02) :142-148
[5]  
COUSER WG, 1988, ANNU REV MED, V39, P517
[6]   Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks [J].
Diekmann, F ;
Campistol, JM .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (03) :562-568
[7]  
DJUKANOVIC LJ, 2004, KIDNEY TRANSPLANTATI, V1, P111
[8]   AUTOLOGOUS IMMUNE COMPLEX NEPHRITIS INDUCED WITH RENAL TUBULAR ANTIGEN .I. IDENTIFICATION AND ISOLATION OF PATHOGENETIC ANTIGEN [J].
EDGINGTON, TS ;
GLASSOCK, RJ ;
DIXON, FJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1968, 127 (03) :555-+
[9]   Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies [J].
Fervenza, FC ;
Fitzpatrick, PM ;
Mertz, J ;
Erickson, SB ;
Liggett, S ;
Popham, S ;
Wochos, DN ;
Synhavsky, A ;
Hippler, S ;
Larson, TS ;
Bagniewski, SM ;
Velosa, JA .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (05) :1288-1292
[10]  
FLEUREN GJ, 1980, CLIN EXP IMMUNOL, V41, P218